![]() |
|
|
Vol. 293, Issue 2, 336-342, May 2000
Department of Neurology, University of Medicine and Dentistry of
New Jersey, Robert Wood Johnson Medical School, Piscataway, New
Jersey
Dopamine neurons from various animal species differ in sensitivity to
the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium (MPP+). Compared with
striatal vesicles isolated from mice, those from rats have a higher
density of the brain vesicular monoamine transporter (VMAT2) and a
greater ability to sequester MPP+, suggesting a larger
storage capacity for MPP+ in rat vesicles. In the present
study, we examined whether striatal VMAT2-containing vesicles might
provide protection against the neurotoxic effects of MPP+
in vivo. Dose-response curves for striatally infused MPP+
were determined in animals pretreated with or without a VMAT2 inhibitor. Ro 4-1284 administration (10 mg/kg i.p.; VMAT2 inhibitor) produced a 5-fold leftward shift in the MPP+ dose-response
curve and a significant lowering of the EC50 concentration for MPP+-induced damage. These findings provide evidence
for a substantial accumulation of MPP+ in VMAT2-containing
vesicles in vivo in the rat striatum and support the hypothesis that
MPP+ sequestration in vesicles can provide protection
against its toxic actions. In mice, VMAT2 inhibition did not reliably
enhance toxicity produced by a striatal infusion of MPP+
or by systemic administration of MPTP. These data suggest that vesicular sequestration of MPP+ may be of less importance
in mice than in rats as relates to protection from the toxin. The
present results also reveal that although VMAT2 inhibition enhanced
striatal MPP+ toxicity in the rat, the potency of
MPP+ in the rat striatum was less than that in mouse
striatum. This implies that there are other factors that either
exacerbate MPP+ toxicity in the mouse or attenuate
MPP+ toxicity in rats.
This article has been cited by other articles:
![]() |
A. L. Numis, E. L. Unger, D. L. Sheridan, A. C. Chisnell, and A. M. Andrews The Role of Membrane and Vesicular Monoamine Transporters in the Neurotoxic and Hypothermic Effects of 1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP) Mol. Pharmacol., September 1, 2004; 66(3): 718 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Eisenhofer, I. J. Kopin, and D. S. Goldstein Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine Pharmacol. Rev., September 1, 2004; 56(3): 331 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1181 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Unger, P. Mazzola-Pomietto, D. L. Murphy, and A. M. Andrews 2'-NH2-MPTP [1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] Depletes Serotonin and Norepinephrine in Rats: A Comparison with 2'-CH3-MPTP [1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine] J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 527 - 533. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. W. Staal, K. A. Hogan, C.-L. Liang, D. C. German, and P. K. Sonsalla In Vitro Studies of Striatal Vesicles Containing the Vesicular Monoamine Transporter (VMAT2): Rat versus Mouse Differences in Sequestration of 1-Methyl-4-phenylpyridinium J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 329 - 335. [Abstract] [Full Text] |
||||